Skip to main content
 

Press Release

Printer Friendly Version View printer-friendly version
<< Back
WAVE Life Sciences to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will participate in a fireside chat and provide a company overview at the JMP Securities Life Sciences Conference at 2:30 PM Eastern Time on Tuesday, June 21, 2016 in New York, NY.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com and follow us on Twitter at @WAVELifeSci and LinkedIn.

Source: WAVE Life Sciences

For WAVE Life Sciences
Media Contact:
Feinstein Kean Healthcare
Jess Rowlands, 202-729-4089
jessica.rowlands@fkhealth.com
or
Investor Contact:
Westwicke Partners
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com